SFI
VTVT icon

Susquehanna Fundamental Investments’s vTv Therapeutics VTVT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-669
Closed -$61K – 1917
2021
Q2 		$61K Sell
669
-218
-25% -$22.1K ﹤0.01% 1613
2021
Q1 		$100K Buy
887
+98
+12% +$9.63K ﹤0.01% 1467
2020
Q4 		$59K Buy
+789
New +$60.5K ﹤0.01% 1448

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Susquehanna Fundamental Investments's VTVT Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of vTv Therapeutics (VTVT) in Q3 2021, closing a stake of 669 shares — an estimated $61K sold.

Susquehanna Fundamental Investments first reported a position in VTVT in Q4 2020 and held it in 3 quarters. The position peaked at $100K in Q1 2021. 31 funds tracked by Wall St. Rank hold VTVT as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining vTv Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 669 vTv Therapeutics shares in Q3 2021, an estimated $61K.
  • Susquehanna Fundamental Investments first reported a position in vTv Therapeutics in Q4 2020 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's vTv Therapeutics position peaked at $100K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.